Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, ...

Dotmatics is Using a New AI-Powered “Lab-in-a-Loop” to Help Big Pharma Bring Therapies to Market – Faster & Cheaper One year ago, the AI hype tsunami hit the world, with promises that LLMs ...

Siemens has agreed to acquire Dotmatics for $5.1 billion, a combination the companies said would use artificial intelligence to speed up development cycles and help make breakthroughs in the life ...

Dotmatics' revenue growth and high profitability will be immediately accretive to Siemens' growth, EBITDA margins and free cash flow, prior to any synergies and special items.

Siemens AG said on Wednesday it will acquire U.S.-based Dotmatics for $5.1 billion from private equity firm Insight Partners to strengthen its Life Sciences portfolio.

Dotmatics®, a leading provider of scientific software that provides end-to-end solutions to connect science, data, and decision making for life sciences R&D, today announced it has signed a ...

Dotmatics centralizes data from disparate sources — applications, databases, and lab instruments — enabling AI algorithms to analyze this information at an unprecedented scale.

Dotmatics, an early research and development company, says they're using AI to help accelerate the timeline in drug discoveries. "The art of drug discovery is really finding drugs in these ...

As Dotmatics continues to innovate, the company aims to push the boundaries of drug discovery through integrated bioinformatics and AI-driven research. Daily insights on business use cases with VB ...

Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced a significant minority investment in BioGlyph, a startup biotech software company that ...

Siemens SIE-0.21%decrease; red down pointing triangle has agreed to acquire Dotmatics for $5.1 billion, a combination the companies said would use artificial intelligence to speed up development ...